• Intelligent AI

  Led · Equity · May 2024

  Intelligent AI has developed a digital platform for insurers and property owners to improve the speed, efficiency, and accuracy of property risk assessments, reducing costs and enabling more appropriate policies. The company is part of the Tech South West Growth Forge accelerator and has secured a multi-million pound UK reseller agreement to take its platform to market. Intelligent AI is headquartered in Exeter and also has an office in Newquay; it was founded in 2020. In May 2024 the company raised £800,000 in new funding. With the latest funding, Intelligent AI plans to double its team and broaden its national footprint. The article does not disclose operating revenue or user metrics. Intelligent AI builds a cloud-based intelligent risk platform that creates digital twins of physical properties to map and quantify risk for insurers. The platform analyzes more than 300 data points, including satellite imagery, to generate accurate property risk data without costly onsite surveys. Its product is aimed at helping insurers write policy terms and predict risk on commercial properties more accurately. The company is part of the Innovate UK–funded KnowRisk Consortium, linking insurance, supply chain and audit risk for a 360-degree enterprise view. Future product development includes a risk report analyzer feature that converts reports into risk mitigation programs. Intelligent AI is led by founder and CEO Anthony Peake and is based in Exeter, UK.

• Neuronostics

  Participated · Seed · Apr 2024

  Neuronostics develops BioEP, a clinically validated digital biomarker platform that analyses standard EEG recordings using eight predefined computational biomarkers and produces a report in under five minutes. The platform is UKCA-marked and ISO-13485 certified and has been validated across 15 NHS sites with over 1,000 recordings. NHS service evaluations are underway at multiple Trusts, including The Royal Wolverhampton NHS Trust and University Hospitals Dorset, and the company has a strategic partnership with Stratus to support scalable US deployment. Neuronostics plans to pursue FDA clearance (with a submission planned for 2026) and to extend the platform to provide brain fingerprints of treatment response in pharmaceutical trials. The company highlights clinical needs such as long diagnostic wait times, high misdiagnosis rates, and the high rate of inconclusive routine EEGs as drivers for its adoption.

• Codices Interactive

  Led · Seed · Jul 2020

  Codices creates tools and content that enable broadcasters, brands, and influencers to build, engage, and monetise audiences through live interactive shows on platforms like Twitch. Its Twitch extension, Quiz Kit, is described as the most-used game show creation tool on the platform globally. The company also produces original shows and offers a carousel of pre-written formats while allowing streamers to create custom shows. Codices has seen increased uptake amid social distancing, entertaining over a million players with Quiz Kit in June. The team plans to roll out additional interactive formats over the next 12 months and is actively seeking new content partners and IP holders. The company closed a seed funding round to support these product and content expansion efforts.

No current team members are available.